Ultragenyx Pharmaceutical Inc.
Symbol: RARE
NASDAQ
43.01
USDMarkedspris i dag
-5.9104
P/E-forhold
0.0654
PEG Ratio
3.54B
MRK Cap
- 0.00%
DIV Udbytte
Ultragenyx Pharmaceutical Inc. (RARE) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2271.64 | 777.1 | 896.7 | 999.1 | |||||||||||||
balance-sheet.row.short-term-investments | 1482.9 | 363.6 | 614.8 | 432.6 | |||||||||||||
balance-sheet.row.net-receivables | 323.63 | 73.4 | 40.4 | 28.4 | |||||||||||||
balance-sheet.row.inventory | 129.93 | 34 | 26.8 | 16.2 | |||||||||||||
balance-sheet.row.other-current-assets | -638.48 | -777.1 | 68.9 | -187.2 | |||||||||||||
balance-sheet.row.total-current-assets | 2554.45 | 732.2 | 883.9 | 856.6 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 1207.13 | 290.6 | 285.7 | 176.2 | |||||||||||||
balance-sheet.row.goodwill | 177.62 | 44.4 | 44.4 | 44.4 | |||||||||||||
balance-sheet.row.intangible-assets | 646.86 | 166.3 | 160.1 | 130.8 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 824.48 | 210.7 | 204.5 | 175.2 | |||||||||||||
balance-sheet.row.long-term-investments | 436.17 | 199.9 | 154.5 | 293.9 | |||||||||||||
balance-sheet.row.tax-assets | 80.98 | 6 | 6.1 | 8.9 | |||||||||||||
balance-sheet.row.other-non-current-assets | 244.34 | 51.7 | 10.7 | 11.6 | |||||||||||||
balance-sheet.row.total-non-current-assets | 2793.09 | 758.8 | 661.5 | 665.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.account-payables | 158.56 | 42.1 | 43.3 | 17.1 | |||||||||||||
balance-sheet.row.short-term-debt | 91.02 | 12.6 | 11.8 | 11.1 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 928.7 | 30.6 | 19.8 | 30.9 | |||||||||||||
Deferred Revenue Non Current | 1736.75 | 862.3 | 0 | 1.5 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 123.45 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 410.65 | 29.2 | 204.7 | 145.6 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3746.75 | 935.2 | 931.7 | 418.5 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 108.94 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.total-liab | 4771.12 | 1215.6 | 1193 | 599.8 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.31 | 0.1 | 0.1 | 0.1 | |||||||||||||
balance-sheet.row.retained-earnings | -13315.3 | -3387.7 | -2781 | -2073.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -1.79 | 0.6 | -6.6 | -1.4 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 13893.21 | 3662.3 | 3140 | 2997.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5347.54 | - | - | - | |||||||||||||
Total Investments | 1852.69 | 563.5 | 620.3 | 726.5 | |||||||||||||
balance-sheet.row.total-debt | 1013.14 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.net-debt | 506.37 | -170.4 | -101.4 | -265.6 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -613.35 | -606.6 | -707.4 | -454 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 29.61 | 26 | 18.2 | 13.2 | |||||||||||||
cash-flows.row.deferred-income-tax | -143.91 | -1.6 | -1.6 | 48.7 | |||||||||||||
cash-flows.row.stock-based-compensation | 140.2 | 135.2 | 130.4 | 105 | |||||||||||||
cash-flows.row.change-in-working-capital | -32.76 | -15.1 | 60.2 | -63.2 | |||||||||||||
cash-flows.row.account-receivables | -45.18 | -22.8 | -12.1 | -5.4 | |||||||||||||
cash-flows.row.inventory | -9.2 | -6.9 | -9.7 | -3.1 | |||||||||||||
cash-flows.row.account-payables | -0.41 | 2.4 | 87.4 | 2.8 | |||||||||||||
cash-flows.row.other-working-capital | 22.04 | 12.2 | -5.4 | -57.5 | |||||||||||||
cash-flows.row.other-non-cash-items | 228.72 | -12.7 | 119.8 | 11.7 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -508.67 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -2.5 | -75 | 0 | |||||||||||||
cash-flows.row.purchases-of-investments | -486.29 | -526.4 | -614.7 | -1012.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 675.52 | 746.2 | 545.1 | 890.9 | |||||||||||||
cash-flows.row.other-investing-activites | -0.66 | -2.5 | -0.8 | -0.9 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 151.13 | 168 | -291.7 | -195.4 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -490.9 | 0 | |||||||||||||
cash-flows.row.common-stock-issued | 354.26 | 379.8 | 10.8 | 78.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | -0.06 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 34.55 | 8.4 | 981.3 | 39.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 388.81 | 388.1 | 501.2 | 118.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.43 | 0.5 | -1.1 | -1.2 | |||||||||||||
cash-flows.row.net-change-in-cash | 34.89 | 85.6 | -172 | -416.7 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 524.23 | 219.4 | 137.6 | 309.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 489.34 | 133.8 | 309.6 | 726.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -508.67 | -474.8 | -380.5 | -338.7 | |||||||||||||
cash-flows.row.capital-expenditure | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.free-cash-flow | -543.61 | -521.6 | -526.6 | -411.8 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 442.59 | 434.2 | 363.3 | 351.4 | |||||||||||||
income-statement-row.row.cost-of-revenue | 59.33 | 45.2 | 28.3 | 16 | |||||||||||||
income-statement-row.row.gross-profit | 383.26 | 389 | 335 | 335.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 652.39 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.operating-expenses | 963.71 | 958.2 | 983.9 | 717.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1023.04 | 1003.5 | 1012.2 | 733.1 | |||||||||||||
income-statement-row.row.interest-income | 29.22 | 26.7 | 11.1 | 1.9 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 27.61 | 26 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.ebitda-caps | -538.27 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -580.45 | -569.2 | -648.9 | -381.7 | |||||||||||||
income-statement-row.row.income-before-tax | -615.22 | -608.5 | -701.7 | -453 | |||||||||||||
income-statement-row.row.income-tax-expense | -1.86 | -1.8 | 5.7 | 1 | |||||||||||||
income-statement-row.row.net-income | -613.35 | -606.6 | -707.4 | -454 |
Ofte stillede spørgsmål
Hvad er Ultragenyx Pharmaceutical Inc. (RARE) samlede aktiver?
Ultragenyx Pharmaceutical Inc. (RARE) samlede aktiver er 1491013000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 236225000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.866.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -6.450.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -1.386.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -1.311.
Hvad er Ultragenyx Pharmaceutical Inc. (RARE) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -606639000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 43169000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 958248000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 118554000.000.